Nature Communications Archives
Jul. 16, 2021—Researchers at Vanderbilt University Medical Center (VUMC) and the Baylor College of Medicine in Houston, Texas, have taken a big step toward developing targeted treatments and vaccines against a family of viruses that attacks the gastrointestinal tract.
Apr. 8, 2021—Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.
Aug. 20, 2020—A small-molecule “scavenger” that reduces inflammation and formation of atherosclerotic plaque in blood vessels in mice potentially could lead to a new approach for treating atherosclerosis in humans, according to researchers at Vanderbilt University Medical Center.
Mar. 23, 2020—Vanderbilt researchers have identified haplotypes, ancestral fragments of DNA, that are associated with hereditary prostate cancer (HPC) in a first-of-its-kind genomic study made possible by the study of prostate cancer patients with family histories of the disease.
Jan. 16, 2020—VUMC researchers have created the world’s first laboratory model of precancerous changes in the lining of the stomach, a scientific tour de force that is helping to unlock the mysteries of gastric cancer development.
Sep. 25, 2019—A study of 280,000 U.S. veterans, including 56,000 African Americans, has identified in greater detail than ever before the genetic architecture of kidney function and chronic kidney disease (CKD), according to researchers at Vanderbilt University Medical Center and their colleagues.
Aug. 8, 2019—Vanderbilt investigators have discovered that, in contrast to prevailing dogma, fibroblasts are not all alike; instead, they have distinctive functions following tissue injury.
May. 3, 2019—Malignant rhabdoid tumor (MRT) is one of the most aggressive and lethal childhood cancers. Although rare — about 20 to 25 new cases are diagnosed annually in the United States — there is no standard effective treatment for the disease, which is driven by loss of an anti-cancer protein called SNF5. The chances are very small that a child will survive a year after MRT diagnosis.